Impact of cardiac dysfunction on morbidity and mortality in liver transplant candidates.
cardiac dysfunction
cardiovascular disease
cirrhosis
cirrhotic cardiomyopathy
liver transplantation
morbidity and mortality
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
30
03
2022
received:
01
02
2022
accepted:
09
04
2022
pubmed:
21
4
2022
medline:
14
7
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
The prognostic role of cardiac dysfunction in cirrhotic patients is increasingly recognized. We studied its impact on morbidity and mortality before and after liver transplantation (LT) including development of post-transplant cardiovascular disease (CVD). In this retrospective study, cirrhotic patients who underwent LT assessment from January 2010 to December 2020 were reviewed. Demographics, cardiac investigations and clinical courses were analyzed to identify the prevalence of cardiac dysfunction and its role in LT outcomes. Survival analysis was performed using Cox proportional hazard regression modelling, with LT as a time-varying covariate and as an interaction variable with cardiac dysfunction. Three hundred and eight patients (70% male) were studied. The median (interquartile range) age at LT assessment was 56 (12) years. Cardiac dysfunction was found in 178 (58%) patients (diastolic, 169; systolic, 26; both, 17) and was significantly associated with hepatorenal syndrome/acute kidney injury and peri- and post-transplant morbidity (adjusted odds ratio [aOR] 1.94, 95% CI 1.06-3.52, P < .001; aOR 2.01, 95% CI 1.06-3.82, P = .033; aOR 1.9, 95% CI 1.01-3.65, P = .023, respectively). Cardiac dysfunction was not associated with mortality before (adjusted hazard ratio [aHR] 1.01, 95% CI .99-1.01) or after LT (aHR .74, 95% CI .4-1.05. Post-transplant CVD (61% cardiac failure) occurred in 36 patients, and there was no significant association with cardiac dysfunction (P = .11). Cardiac dysfunction was common in LT candidates and was significantly associated with morbidity before and after LT. Studies on the role of advanced echocardiographic parameters to improve diagnosis of cardiac dysfunction and optimize LT outcomes are needed.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14682Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Yoon KT, Liu H, Lee SS. Cirrhotic cardiomyopathy. Curr Gastroenterol Rep. 2020;22(9):45.
Koshy AN, Gow PJ, Han HC, et al. Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. Eur Heart J Qual Care Clin Outcomes. 2020;6(4):243-253.
Chahal D, Liu H, Shamatutu C, Sidhu H, Lee SS, Marquez V. Review article: comprehensive analysis of cirrhotic cardiomyopathy. Aliment Pharmacol Ther. 2021;53(9):985-998.
Rachwan RJ, Kutkut I, Hathaway TJ, et al. Postoperative atrial fibrillation and flutter in liver transplantation: an important predictor of early and late morbidity and mortality. Liver Transpl. 2020;26(1):34-44.
Izzy MV, LB Lin G. Redfining cirrhotic caridomyopathy for the modern era. Hepatology. 2020;71(1).
ANZLTR. 31st Annual Report on Liver and Intestinal Transplantation Activity in Australia and New Zealand. Australia and New Zealand Liver Transplant Registry. Published: 2019. Accessed: 28/07/2021, 2021.
Durand F, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. J Hepatol. 2019;70(4):745-758.
Nicolau-Raducu R, Gitman M, Ganier D, et al. Adverse cardiac events after orthotopic liver transplantation: a cross-sectional study in 389 consecutive patients. Liver Transpl. 2015;21(1):13-21.
VanWagner LBLB, Levitsky J, Wilkins JT, Abecassis MM, Skaro AI, Lloyd-Jones DM. High early cardiovascular mortality following liver transplantation. Liver Transplant. 2014;20(11):1306-1316.
Wiese SHJ, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev. 2014;11.
Kwon HM, Moon YJ, Jung KW, et al. Appraisal of cardiac ejection fraction with liver disease severity: implication in post-liver transplantation mortality. Hepatology (Baltimore, Md). 2020;71(4):1364-1380.
Sampaio F, Pimenta J. Left ventricular function assessment in cirrhosis: current methods and future directions. World J Gastroenterol. 2016;22(1):112-125.
Sonny A, Ibrahim A, Schuster A, Jaber WA, Cywinski JB. Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. Clin Transplant. 2016;30(9):986-993.
Mittal CQW, Singla S, Ahmad U, Huang MA. Pre-transplant left ventricular diastolic dysfunction is associated with post transplant acute graft rejection and graft failure. Dig Dis Sci. 2014;59:674-680.
Raevens S, De Pauw M, Geerts A, et al. Prevalence and outcome of diastolic dysfunction in liver transplantation recipients. Acta Cardiol. 2014;69(3):273-280.
Robertson M, Chung W, Liu D, et al. Cardiac risk stratification in liver transplantation: results of a tiered assessment protocol based on traditional cardiovascular risk factors. Liver Transpl. 2021;27(7):1007-1018.
Koshy AN, Gow PJ, Han HC, et al. Sudden cardiac death following liver transplantation: incidence, trends and risk predictors. Int J Cardiol. 2021;327:171-174.
Nagueh SFSO, Appleton CP, Byrd BF, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
Ruíz-del-Árbol L, Achécar L, Serradilla R, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology (Baltimore, Md). 2013;58(5):1732-1741.
Izzy M, Soldatova A, Sun X, et al. Cirrhotic cardiomyopathy predicts posttransplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transpl. 2021;27(6):876-886.
Singh AD, Ford A, Lyu R, et al. Impact of cirrhotic cardiomyopathy diagnosed according to different criteria on patients with cirrhosis awaiting liver transplantation: a retrospective cohort study. Dig Dis Sci. 2022.
Zhou J, Bai L, Zhang XJ, Li H, Cai J. Nonalcoholic fatty liver disease and cardiac remodeling risk: pathophysiological mechanisms and clinical implications. Hepatology. 2021;74(5):2839-2847.
VanWagner LB, Harinstein ME, Runo JR, et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. Am J Transplant. 2018;18(1):30-42.
Hogan BJ, Gonsalkorala E, Heneghan MA. Evaluation of coronary artery disease in potential liver transplant recipients. Liver Transpl. 2017;23(3):386-395.
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
Tamaki N, Kurosaki M, Takahashi Y, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol. 2021;36(10):2960-2966.
Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903-913.
Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42(2):439-447.
Khurmi NSCY, Eric Steidley D, Singer AL, Hewitt WR, Reddy KS, Moss AA. Hospitalizations for cardiovascular disease after liver transplantation in the United States. Liver Transplant. 2018;24:1398-1410.
Registry AaNZCT. Evaluation for cirrhotic cardiomyopathy: A prospective study of global cardiac function in decompensated cirrhosis and its clinical significance. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000895886 Published: 2021. Updated: 8/7/2021. Accessed.
GESA AGW 2021 virtual SS-SS. hepatology clinical. J Gastroenterol Hepatol. 2021;36(12):38-85.
Qureshi W, Mittal C, Ahmad U, et al. Clinical predictors of post-liver transplant new-onset heart failure. Liver Transpl. 2013;19(7):701-710.